Ventyx Biosciences, Inc. ( (VTYX) ) has released its Q4 earnings. Here is a breakdown of the information Ventyx Biosciences, Inc. presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company that develops innovative oral therapies targeting autoimmune, inflammatory, and neurodegenerative diseases, with a focus on NLRP3 inhibitors and treatments for inflammatory bowel disease.